COMPARATIVE STUDY OF ANTI-CANCER ACTIVITY OF APREMILAST AND IMATINIB – IN VITRO STUDY OF COLON CANCER
DOI:
https://doi.org/10.22159/ajpcr.2025v18i10.55373Keywords:
Anti-cancer activity, Apremilast, Imatinib, MTT assay, HT-29 colorectal cell lineAbstract
Objective: Among oral phosphodiesterase (PDE) inhibitors, PDE-4 inhibitors such as apremilast display anti-inflammatory effects in numerous in vitro and in vivo studies. Apremilast suppresses the release of various cytokines, interleukins, and other inflammatory mediators, while also reducing the formation of reactive oxygen species. Moreover, it may act as a pro-apoptotic agent in colon and pancreatic cancer cells. Meanwhile, imatinib, a tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, chronic myeloid leukemia, and other cancers, also shows anti-cancer activity. This study evaluates the effects of both PDE-4 inhibitors and imatinib on HT-29 colon cancer cells using the MTT (methylthiazolyldiphenyl-tetrazolium bromide) assay.
Methods: HT-29 cell lines are incubated at 37°C for 24 h, and drug samples are added at various concentrations. An ultraviolet spectrophotometer was used to add 1 mL of dimethyl sulfoxide. 50% inhibition concentration was measured graphically.
Results: The maximum half of the cell inhibitory 56.09% is at a 31.2 μg/mL concentration of apremilast, and the maximum half of the cell inhibitory 49.17% is at a 62.5 μg/mL concentration of imatinib.
Conclusion: Hence, this study concludes that the percentage of cell inhibition for apremilast is equally potent as imatinib, but at higher concentrations, the percentage of cell viability is less for imatinib than apremilast in colon cancer cell lines. Further studies might be required on humans to prove the effect of the drug on cancer patients.
Downloads
References
1. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem. 1958;232(2):1077-91. doi: 10.1016/S0021-9258(19)77423-7, PMID 13549488
2. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366-98. doi: 10.1016/j. pharmthera.2005.07.003, PMID 16102838
3. Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev. 1988;40(1):49-84. doi: 10.1016/S0031- 6997(25)00016-X, PMID 3064106
4. Manganiello VC, Taira M, Degerman E, Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell Signal. 1995;7(5):445-55. doi: 10.1016/0898-6568(95)00017-j, PMID 8562305
5. Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: Is rolipram as effective as amitriptyline? Eur J Clin Pharmacol. 1991;40(2):127-9. doi: 10.1007/BF00280065, PMID 2065693
6. Fala L. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8:105-10. PMID 26629274
7. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-90. doi: 10.1016/j.bcp.2012.01.001, PMID 22257911
8. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413-9. doi: 10.4049/jimmunol.1001829, PMID 21084670
9. Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008;2008:419-26. doi: 10.1182/asheducation-2008.1.419, PMID 19074120
10. Stockert JC, Horobin RW, Colombo LL, Blázquez-Castro A. Tetrazolium salts and formazan products in cell biology: Viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem. 2018;120(3):159-67. doi: 10.1016/j.acthis.2018.02.005, PMID 29496266
11. Kumar SS, Kannan M, Panneerselvam A. In vitro anticancer activity of methanolic extract of Tinospora cordifolia on A549 lung cancer cell line. Int J Appl Pharm. 2018;10(5):159-62.
12. Das K, Chakraborty B, Bhowmik D. In vitro anticancer activity of ethanolic extract of Ocimum sanctum on HeLa cell lines. Int J Appl Pharm. 2020;12(4):45-9.
13. Sengupta R, Sun T, Warrington NM, Rubin JB. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci. 2011;32(6):337-44. doi: 10.1016/j.tips.2011.02.015
14. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110(7):1045-52. doi: 10.1172/JCI15506, PMID 12370283
15. McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107. doi: 10.1186/ar3041, PMID 20525198
16. Poole RM, Ballantyne AD. Apremilast: First global approval. Drugs. 2014;74(7):825-37. doi: 10.1007/s40265-014-0218-4, PMID 24797159
17. Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, et al. Apremilast induces apoptosis of human colorectal cancer cells with mutant KRAS. Anticancer Res. 2017;37:3833-9.
18. Saranya M, Punnagai K, David DC, Anusha D. Evaluation of anticancer effects of vasopressin receptor blocker in colon cancer - an in vitro study. Res J Pharm Technol. 2020;13(1):77-80. doi: 10.5958/0974- 360X.2020.00014.1
19. Samei L, Yaling P, Lihua Y, Yan Z, Shuyan J. Effects and mechanism of imatinib in inhibiting Colon cancer cell proliferation. Med Sci Monit. 2016;22:4126-31. doi: 10.12659/msm.898152, PMID 27799652
Published
How to Cite
Issue
Section
Copyright (c) 2025 PARVATHAREDDY SOWMYA, BALAJI C, PAREPALLI SURESH, KAVITHA RAMASAMY
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
